NASDAQ:BLSM BlossomHill Therapeutics Q2 2026 Earnings Results & Report $14.92 -0.34 (-2.23%) As of 04:00 PM Eastern BlossomHill Therapeutics missed analyst earnings expectations in its Q2 2026 results, released September 18, 2026. The company reported EPS of -$8.75 versus the -$0.84 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 18, 2026TimeBefore Market OpensConference Call7:00 AM ET BlossomHill Therapeutics EPS ResultsActual EPS-$8.75Consensus EPS -$0.84Beat/MissMissed by -$7.91One Year Ago EPSN/ABlossomHill Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) BlossomHill Therapeutics Q2 2026 Earnings FAQ Did BlossomHill Therapeutics beat earnings estimates for Q2 2026? BlossomHill Therapeutics (NASDAQ:BLSM) reported earnings of -$8.75 per share for Q2 2026, missing the consensus estimate of -$0.84. The report was announced on Friday, September 18, 2026. BlossomHill Therapeutics Earnings HeadlinesBlossomHill Therapeutics Inc BLSMOctober 8, 2026 | morningstar.comMBLSM Share News TodayOctober 4, 2026 | uk.investing.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)BlossomHill Therapeutics average analyst price target raised 10.53% to $37.48October 2, 2026 | msn.comBlossomHill Therapeutics Stock Price HistorySeptember 29, 2026 | investing.comBlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic CancerSeptember 28, 2026 | globenewswire.comSee More BlossomHill Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BlossomHill Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BlossomHill Therapeutics and other key companies, straight to your email. Email Address About BlossomHill TherapeuticsBlossomHill Therapeutics (NASDAQ:BLSM) Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc. is headquartered in San Diego, California.View BlossomHill Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
